GLP-1 receptor agonists work with your biology instead, targeting the specific hormonal pathways that regulate appetite, satiety, and metabolic function
Telling her to "just take the medication" dismisses the importance of breastfeeding
Available from: Accessed: 19 Sep 2025 Jastreboff AM, Kaplan LM, Fras JP et al (2023) Triplehormone-receptor agonist retatrutide for obesity: a phase 2 trial
Some people may feel full quickly, feel bloated after eating, or notice more burping than usual
If it has Lilly on the box, thats the goal we have. The GLP-1 market has expanded from under $12 billion in 2022 to a roughly $65 billion annualized run rate by mid-2025
A: Yes, according to FDA prescribing information, all GLP-1 medications available through Ro are administered as subcutaneous (under-skin) injections: Frequency : Once weekly (same day each week) Injection sites : Abdomen, thigh, or upper arm (rotate sites) Needle size : Very small (similar to insulin needles) Administration time : Less than 1 minute Most members report that injection anxiety diminishes significantly after first few doses